FDA Clarifies CBER Control Over Blood NDA And ANDA Paths

Regulatory affairs leads managing submissions for blood processing solutions, plasma volume expanders, or anticoagulant collection products need to confirm center jurisdiction before filing, CBER, not CDER, retains regulatory authority over a defined subset of NDAs and ANDAs that most submission teams default to routing through the wrong center.

The FDA's Center for Biologics Evaluation and Research has published updated guidance clarifying which NDA and ANDA product categories fall under its jurisdiction. While CDER handles the overwhelming majority of NDA and ANDA reviews, CBER maintains authority over a specific set of blood-related drug products. These include red blood cell rejuvenation solutions, anticoagulant solutions used in donor blood collection, sterile bags containing anticoagulants for umbilical cord blood collection, plasma volume expansion products indicated for hypovolemia, and solutions used in storage of leuko-reduced apheresis platelets under standard blood banking conditions.

The ANDA landscape under CBER is narrower still. Only a small number of ANDAs currently sit within CBER's remit, primarily those tied to blood transfusion products. Sponsors filing generics in adjacent therapeutic areas should verify center assignment early in development planning, as a misrouted submission triggers procedural delays that compound against 21 CFR Part 314 filing timelines.

For QA and regulatory leads, the practical read is straightforward: product classification determines the review center, and the review center determines which guidance documents, standard operating procedures, and review management principles govern the submission. CBER publishes its own Biologics Procedures (SOPPs) and Good Review Management Principles distinct from CDER's frameworks, meaning a submission prepared against the wrong center's expectations may require substantive rework before acceptance.

Sponsors seeking center determination for borderline products can reference CBER's published list of approved NDAs and ANDAs with supporting documents, or consult the Master Files guidance for CBER-regulated products. The FDA contact point for biologics inquiries remains 1-888-INFO-FDA.

Confirmed center jurisdiction at the pre-submission stage remains the most direct way to avoid filing refusals and clock resets under the NDA review cycle.

Source: FDA Center for Biologics Evaluation and Research via What's New Vaccines Blood Biologics RSS Feed, September 8, 2026.